Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer

Journal Title: Journal of Oncobiomarkers - Year 2015, Vol 2, Issue 1

Abstract

mTOR is a serine/threonine kinase and plays a critical role in mammalian cell growth, survival, and metabolism. mTOR is present in two cellular complexes: mTORC1 and mTORC2. Dysregulation of the mTOR pathway has been related to tumorigenesis, poor prognosis and/or chemotherapy resistance in a variety of malignancies. Inhibition of mTORC1 by Rapamycin and its analogs has been explored to treat a number of tumors. However, the effectiveness of atient response is limited and not all patients respond. Second generation of mTOR inhibitors have recently been developed to target mTOR kinase activity and to suppress both mTORC1 and mTORC2. Dual mTORC1/mTORC2 inhibitors generally are more efficacious in preclinical studies and clinical trials. We and others have recently found that dual mTORC1/mTORC2 inhibitors sensitize T-cell acute lymphocytic leukemia and rhabdomyosarcoma cells to DNA damaging agents by suppression of expression of FANCD2 of the Fanconi anemia pathway, an important DNA repair mechanism that is associated with drug resistance of multiple types of cancer. This review will highlight mTOR and the Fanconi anemia pathway in cancer, with a particular attention to our newly discovered connection between mTOR and the Fanconi anemia pathway.

Authors and Affiliations

Fukun Guo

Keywords

Related Articles

IRF4 as an Oncogenic Biomarker for Hematological Malignancies

The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interac...

Recent Advances in Managementof Prostate Cancer

Prostate cancer is the second most common cancer in males worldwide and the incidence is increasing due to ageing population, screening facilities and rising awareness. This is a disease of the elderly and is biologicall...

Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer

mTOR is a serine/threonine kinase and plays a critical role in mammalian cell growth, survival, and metabolism. mTOR is present in two cellular complexes: mTORC1 and mTORC2. Dysregulation of the mTOR pathway has been rel...

The Relative Fewness of Renal Metastases in Lung Cancer is Probably Explicable with the “Erythrocyte Associated Necrosis Factor” which may be an Oncobiomarker

There is profundity of lung cancer cells thrown into the circulation with each heart beat and the quantity of the quarter of the cardiac stroke volume being delivered to the kidneys. Despite both of these attractive attr...

Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients

Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain w...

Download PDF file
  • EP ID EP240038
  • DOI 10.13188/2325-2340.1000008
  • Views 119
  • Downloads 0

How To Cite

Fukun Guo (2015). Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer. Journal of Oncobiomarkers, 2(1), 1-5. https://europub.co.uk/articles/-A-240038